Agents which Regulate, Inhibit, or Modulate the Activity and/or Expression of Connective Tissue Growth Factor (CTGF) to Lower Intraocular Pressure

摘要

Uses are described for glycogen synthase kinase (GSK-3) inhibitors, or cyclin-dependent kinase (CDK) inhibitors, selected from the group consisting of: SB-216763, alsterpaullone, 9-cyanopaullone, and kenopaullone; GW-8510, purvalanol A, and roscovitine; €ƒ€ƒ€ƒ
that inhibit expression, signalling or biological functions of connective tissue growth factor (CTGF), for the manufacture of a medicament for the treatment of glaucoma, and for preventing the visual field loss associated with Primary Open Angle Glaucoma (POAG).